Cytokinetics posts GALACTIC-HF presentation on omecamtiv mecarbil, RDW in HFrEF patients

Cytokinetics

Cytokinetics

CYTK

0.00
  • Cytokinetics published GALACTIC-HF trial results linking higher baseline red cell distribution width to worse outcomes in chronic HFrEF patients.
  • The analysis used a primary endpoint of first heart-failure event or cardiovascular death.
  • Higher RDW quartiles showed greater baseline disease burden, including more anemia, lower KCCQ-TSS, higher NYHA III/IV rates, higher NT-proBNP.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.